Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ProShares UltraPro Short S&P500 ETF
SPXU
5
T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ
US Stock MarketDetailed Quotes
HCWB HCW Biologics
- 7.030
- -0.603-7.89%
Close May 5 16:00 ET
- 7.350
- +0.320+4.55%
Pre 04:19 ET
7.90MMarket Cap-0.23P/E (TTM)
7.778High6.360Low38.57KVolume7.300Open7.633Pre Close267.02KTurnover7.66%Turnover RatioLossP/E (Static)1.12MShares100.80052wk High-1.17P/B3.54MFloat Cap6.36052wk Low--Dividend TTM503.73KShs Float311.000Historical High--Div YieldTTM18.57%Amplitude6.360Historical Low6.922Avg Price1Lot Size
HCW Biologics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -9.68%2.57M | -70.18%394.8K | -50.02%426.42K | -0.63%618.85K | 2,590.14%1.13M | -57.72%2.84M | -1.31%1.32M | -52.84%853.1K | 37.18%622.81K | -98.66%41.88K |
| Operating revenue | -9.68%2.57M | -70.18%394.8K | -50.02%426.42K | -0.63%618.85K | 2,590.14%1.13M | -57.72%2.84M | -1.31%1.32M | -52.84%853.1K | 37.18%622.81K | -98.66%41.88K |
| Cost of revenue | -29.54%1.61M | -70.52%315.84K | -49.71%341.14K | -12.73%438.44K | 1,644.34%511.97K | -44.84%2.28M | -0.17%1.07M | -53.13%678.33K | 74.93%502.4K | -97.79%29.35K |
| Gross profit | 71.21%959.4K | -68.75%78.96K | -51.20%85.29K | 49.84%180.41K | 4,805.03%614.75K | -78.33%560.36K | -5.84%252.65K | -51.69%174.78K | -27.81%120.41K | -99.30%12.53K |
| Operating expense | -28.95%14M | -57.36%3.86M | -11.06%2.83M | 13.07%3.62M | 50.91%8.11M | 11.55%19.71M | 52.63%9.06M | -27.48%3.18M | -12.87%3.2M | 46.39%5.37M |
| Selling and administrative expenses | -7.34%6.03M | -9.79%1.44M | 8.50%1.57M | 0.30%1.53M | 94.16%5.92M | -18.47%6.51M | -42.05%1.59M | -14.93%1.45M | -9.93%1.52M | 65.21%3.05M |
| -General and administrative expense | -7.34%6.03M | -9.79%1.44M | 8.50%1.57M | 0.30%1.53M | 94.16%5.92M | -18.47%6.51M | -42.05%1.59M | -14.93%1.45M | -9.93%1.52M | 65.21%3.05M |
| Research and development costs | -16.77%6.39M | -50.87%1.05M | -28.82%1.19M | 25.52%2.03M | -5.87%2.12M | -17.80%7.68M | -27.09%2.14M | -37.05%1.67M | -17.93%1.62M | 26.05%2.26M |
| Depreciation amortization depletion | 4.05%277.55K | -4.86%74.5K | 9.97%69.37K | 2.81%66.62K | -3.08%67.08K | -21.18%266.76K | -69.17%78.31K | 97.51%63.08K | 282.51%64.8K | 94.39%69.21K |
| -Depreciation and amortization | 4.05%277.55K | -4.86%74.5K | 9.97%69.37K | 2.81%66.62K | -3.08%67.08K | -21.18%266.76K | -69.17%78.31K | 97.51%63.08K | 282.51%64.8K | 94.39%69.21K |
| Provision for doubtful accounts | -75.24%1.3M | ---- | ---- | ---- | ---- | --5.25M | ---- | ---- | ---- | ---- |
| Operating profit | 31.88%-13.04M | 57.04%-3.78M | 8.72%-2.74M | -11.64%-3.44M | -39.79%-7.49M | -26.97%-19.15M | -55.39%-8.81M | 25.30%-3M | 12.16%-3.08M | -185.01%-5.36M |
| Net non-operating interest income expense | -309.28%-1.16M | -54,591.36%-775.41K | -133.85%-223.36K | -67.17%-159.67K | 0 | -123.47%-283.04K | 101.51%1.42K | -196.77%-95.51K | -95.51K | -93.44K |
| Non-operating interest expense | 309.28%1.16M | 54,591.36%775.41K | 133.85%223.36K | 67.17%159.67K | --0 | 123.47%283.04K | -101.51%-1.42K | 196.77%95.51K | --95.51K | --93.44K |
| Other net income (expense) | -184.30%-15.82M | 163.22%1.19M | 49.03%-938.15K | -938.20%-11.68M | -93.32%25.6K | -1,926.43%-5.57M | -646.80%-1.88M | -1,437.15%-1.84M | -218,081.40%-1.12M | 317.31%383.32K |
| Special income (charges) | -142.11%-15.91M | 92.41%-148.95K | 54.25%-949.46K | -628.62%-10.39M | ---- | ---6.57M | ---1.96M | ---2.08M | ---1.43M | ---- |
| -Less:Other special charges | 142.11%15.91M | -92.41%148.95K | -54.25%949.46K | 628.62%10.39M | ---- | --6.57M | --1.96M | --2.08M | --1.43M | ---- |
| Other non- operating income (expenses) | -91.35%86.99K | 1,447.59%1.33M | -95.18%11.31K | -525.88%-1.28M | -93.32%25.6K | 230.10%1.01M | -74.86%86.24K | 70.55%234.75K | 58,352.52%301.62K | 317.31%383.32K |
| Income before tax | -20.12%-30.02M | 68.42%-3.37M | 20.98%-3.9M | -254.99%-15.28M | -47.28%-7.47M | -67.74%-24.99M | -97.10%-10.68M | -26.17%-4.94M | -22.61%-4.3M | -146.48%-5.07M |
| Income tax | ||||||||||
| Net income | -20.12%-30.02M | 68.42%-3.37M | 20.98%-3.9M | -254.99%-15.28M | -47.28%-7.47M | -67.74%-24.99M | -97.10%-10.68M | -26.17%-4.94M | -22.61%-4.3M | -146.48%-5.07M |
| Net income continuous Operations | -20.12%-30.02M | 68.42%-3.37M | 20.98%-3.9M | -254.99%-15.28M | -47.28%-7.47M | -67.74%-24.99M | -97.10%-10.68M | -26.17%-4.94M | -22.61%-4.3M | -146.48%-5.07M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -20.12%-30.02M | 68.42%-3.37M | 20.98%-3.9M | -254.99%-15.28M | -47.28%-7.47M | -67.74%-24.99M | -97.10%-10.68M | -26.17%-4.94M | -22.61%-4.3M | -146.48%-5.07M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -20.12%-30.02M | 68.42%-3.37M | 20.98%-3.9M | -254.99%-15.28M | -47.28%-7.47M | -67.74%-24.99M | -97.10%-10.68M | -26.17%-4.94M | -22.61%-4.3M | -146.48%-5.07M |
| Basic earnings per share | -10.00%-30.8 | 73.33%-3.2 | 28.57%-4 | -233.33%-16 | -42.86%-8 | -66.67%-28 | -100.00%-12 | -27.27%-5.6 | -20.00%-4.8 | -133.33%-5.6 |
| Diluted earnings per share | -10.00%-30.8 | 73.33%-3.2 | 28.57%-4 | -233.33%-16 | -42.86%-8 | -66.67%-28 | -100.00%-12 | -27.27%-5.6 | -20.00%-4.8 | -133.33%-5.6 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now